Cibus (NASDAQ:CBUS) Posts Quarterly Earnings Results, Misses Expectations By $0.10 EPS

Cibus (NASDAQ:CBUS) issued its quarterly earnings data on Thursday. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.10), FiscalAI reports. The company had revenue of $0.99 million for the quarter, compared to analyst estimates of $1.70 million. Cibus had a negative return on equity of 200.87% and a negative net margin of 2,366.33%.

Here are the key takeaways from Cibus’ conference call:

• Revenue increased 35% year to date to $2.7 million, driven by Sustainable Ingredients collaboration agreements, while R&D and SG&A expenses declined by nearly $5 million year over year.
• Cibus expects additional scale-up orders for its biofragrance program in the second half of 2026 and estimates a potential $20 million–$40 million annual revenue opportunity when fully commercialized.
• The company pushed its expected initial Latin American rice commercialization from late 2027 to 2028; U.S. commercialization remains targeted for 2029, and royalties are not expected to begin until 2028.
• Cibus highlighted expanding rice partnerships, including Interoc’s increase from two traits to five, and described a potential rice royalty opportunity exceeding $200 million annually at peak adoption across the Americas.
• Cibus had $20.4 million in cash at June 30 and expects funding only into early Q1 2027, while its projected annualized net cash usage exiting 2026 increased to approximately $35 million as it invests in technology and personnel.

Cibus Price Performance

Cibus stock traded down $0.23 during trading hours on Friday, hitting $1.67. The company had a trading volume of 194,594 shares, compared to its average volume of 453,435. The firm has a 50-day moving average of $1.64 and a 200 day moving average of $1.97. The firm has a market cap of $127.47 million, a PE ratio of -0.85 and a beta of 1.61. Cibus has a one year low of $1.09 and a one year high of $4.19.

Analysts Set New Price Targets

Several analysts have issued reports on CBUS shares. Wall Street Zen raised Cibus from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Weiss Ratings lowered Cibus from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 29th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $9.00.

Hedge Funds Weigh In On Cibus

Institutional investors and hedge funds have recently made changes to their positions in the company. PACK Private Wealth LLC bought a new position in shares of Cibus during the fourth quarter worth approximately $27,000. Qube Research & Technologies Ltd bought a new stake in Cibus in the 2nd quarter valued at $39,000. Bank of America Corp DE grew its holdings in Cibus by 113.4% in the 4th quarter. Bank of America Corp DE now owns 35,536 shares of the company’s stock valued at $99,000 after buying an additional 18,885 shares in the last quarter. AQR Capital Management LLC acquired a new position in Cibus in the 1st quarter valued at $73,000. Finally, Squarepoint Ops LLC bought a new position in Cibus during the 3rd quarter worth $62,000. Institutional investors and hedge funds own 33.81% of the company’s stock.

Cibus Company Profile

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.